Multimodal environmental modification (MEMO) and therapeutic urinary diets are the only interventions with sufficient evidence to recommend as primary treatment for feline idiopathic cystitis (FIC). All other commonly used therapies — anti-inflammatories, glycosaminoglycans (GAGs), prazosin, amitriptyline, and intravesical lidocaine — lack adequate evidence to support routine use.New Zealand Vet…
FIC accounts for 54–69% of feline lower urinary tract disease cases and is a diagnosis of exclusion, requiring elimination of urolithiasis, bacterial cystitis, urethral plugs, neoplasia, and anatomical defects before the diagnosis is confirmed.Journal of Feli…+1 Bacterial cystitis is uncommon in cats under 10 years of age, with urinary tract infections identified by culture in approximately 2% of cats presenting with periuria in that age group, making empirical antibiotics inappropriate without a positive culture and susceptibility result.Journal of the…
MEMO is the cornerstone of long-term management. Cats followed for 10 months under a MEMO protocol showed significant reductions in lower urinary tract signs.AAHA Clinical G… The stress-FIC link is well established — recognized triggers include indoor lifestyle, dry diet, cohabitation and conflict with other cats, lack of environmental enrichment, and abrupt environmental changes.Journal of Vete…+1 Not all cats require intensive MEMO; the program should be tailored to the individual cat's needs and the owner's capacity to implement changes.AAHA Clinical G…
Dietary modification is the second pillar of management. Therapeutic urinary diets have good evidence for reducing recurrent episodes, and increasing dietary moisture content provides additional benefit — wet food or water supplementation is recommended alongside any prescription urinary diet.New Zealand Vet… Diet is the only intervention associated with improved outcome in a prospective randomized trial for FIC.Journal of Vete…
Anti-inflammatory drugs, including meloxicam, do not reduce recurrence or accelerate clinical recovery. Meloxicam at 0.1 mg/kg PO on day 1 followed by 0.05 mg/kg PO on days 2–5 produced recurrent urethral obstruction in 22% of treated cats versus 26% in placebo controls — a non-significant difference.Journal of Feli… General demeanour and pain on abdominal palpation improved in both groups equally during hospitalization.Journal of Feli… No anti-inflammatory drug studied has demonstrated efficacy for FIC.New Zealand Vet…
Prazosin shows no benefit in placebo-controlled trials. Three placebo-controlled studies found no evidence for its use; a single retrospective paper suggested possible utility, but this is insufficient to support routine prescription.New Zealand Vet…
Oral GAGs (e.g., glucosamine) are not supported by evidence. Four papers examining GAGs found insufficient evidence for their use.New Zealand Vet… Intravesical pentosan polysulfate sodium (PPS) at 30 mg instilled at catheter placement and repeated at 24 and 48 hours produced no difference in recurrent urethral obstruction compared to saline placebo.Journal of Feli… Intravesical GAG instillation in a pilot study showed zero re-obstructions in treated cats versus re-obstruction in 3 of 7 placebo cats, but this did not reach statistical significance (P = 0.06) and is not yet sufficient to recommend routine use.Journal of Feli…
Amitriptyline is not supported for short-term use and should be reserved for refractory, chronically recurrent cases where two studies showed no short-term benefit; one long-term study suggested possible utility in a subset of refractory cats.New Zealand Vet… Intravesical lidocaine instillation is not a useful treatment strategy.New Zealand Vet…
Recurrence rates are high regardless of treatment, ranging from 15–65% across studies, and cats with higher recurrence frequency are significantly more likely to be euthanized due to FIC.Journal of Feli…+1 Mortality associated with FIC — including deaths and euthanasia — has been reported in the range of 5–21%.Journal of Feli…
| Intervention | Protocol | Evidence | Key Caveat |
|---|---|---|---|
| MEMO | Individualized environmental enrichment, stress reduction | Significant reduction in lower urinary tract signs at 10 months AAHA Clinical G… | Must be tailored to cat and owner; not all cats need intensive modification AAHA Clinical G… |
| Therapeutic urinary diet + increased moisture | Prescription urinary diet; wet food or water supplementation | Good evidence for reducing recurrence New Zealand Vet…+1 | Only intervention with prospective randomized trial support Journal of Vete… |
| Meloxicam | 0.1 mg/kg PO day 1; 0.05 mg/kg PO days 2–5 | Recurrence 22% (treated) vs 26% (placebo); no significant difference Journal of Feli… | Not recommended; no benefit over placebo |
| Prazosin | Various | No benefit in 3 placebo-controlled trials New Zealand Vet… | Single retrospective paper insufficient to support use |
| Oral GAGs / glucosamine | Various | 4 studies show insufficient evidence New Zealand Vet… | Not recommended |
| Intravesical PPS | 30 mg in saline ×3 over 48 h | No difference in re-obstruction vs saline Journal of Feli… | Not recommended |
| Intravesical GAGs | Single instillation at catheterization | 0/9 re-obstruction (treated) vs 3/7 (placebo); P = 0.06 Journal of Feli… | Pilot data only; not yet recommended |
| Intravesical lidocaine | Single instillation | Not a useful treatment strategy New Zealand Vet… | Not recommended |
| Amitriptyline | Short-term | Not supported New Zealand Vet… | Reserve for refractory chronic cases only |
Would you like guidance on the specific components of a MEMO protocol and how to prioritize them for a cat with recurrent obstructive FIC?